[Therapeutic value of the long-term administration of beta-adrenergic blockaders after myocardial infarct].
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000526:Alprenolol / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D006801:Humans; D008790:Metoprolol / Q000008:administration & dosage; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D010919:Placebos; D011217:Practolol / Q000008:administration & dosage; D011433:Propranolol / Q000008:administration & dosage; D011897:Random Allocation; D013015:Sotalol / Q000008:administration & dosage; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D013999:Timolol; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; D008790:Metoprolol; D011217:Practolol
Lechebna stoĭnost na prodŭlzhitelnoto prilozhenie na beta-adrenergichni blokeri sled miokarden infarkt.